Program Information
A Feasibility Study of Independent Dose Verification for CyberKnife
A Sato1*, T Noda1 , Y Keduka1 , T Kawajiri1 , M Itano2 , T Yamazaki2 , H Tachibana3 , (1) Itabashi chuo Medical Center, Itabashi, Tokyo, (2) Inagi Municipal Hospital, Inagi, Tokyo, (3) National Cancer Center, Kashiwa, Chiba
Presentations
TH-AB-201-1 (Thursday, August 4, 2016) 7:30 AM - 9:30 AM Room: 201
Purpose:CyberKnife irradiation is composed of tiny-size, multiple and intensity-modulated beams compared to conventional linacs. Few of the publications for Independent dose calculation verification for CyberKnife have been reported. In this study, we evaluated the feasibility of independent dose verification for CyberKnife treatment as Secondary check.
Methods:The followings were measured: test plans using some static and single beams, clinical plans in a phantom and using patient’s CT. 75 patient plans were collected from several treatment sites of brain, lung, liver and bone. In the test plans and the phantom plans, a pinpoint ion-chamber measurement was performed to assess dose deviation for a treatment planning system (TPS) and an independent verification program of Simple MU Analysis (SMU). In the clinical plans, dose deviation between the SMU and the TPS was performed.
Results:In test plan, the dose deviations were 3.3±4.5%, and 4.1±4.4% for the TPS and the SMU, respectively. In the phantom measurements for the clinical plans, the dose deviations were -0.2±3.6% for the TPS and -2.3±4.8% for the SMU. In the clinical plans using the patient’s CT, the dose deviations were -3.0±2.1% (Mean±1SD). The systematic difference was partially derived from inverse square law and penumbra calculation.
Conclusion:The independent dose calculation for CyberKnife shows -3.0±4.2% (Mean±2SD) and our study, the confidence limit was achieved within 5% of the tolerance level from AAPM task group 114 for non-IMRT treatment. Thus, it may be feasible to use independent dose calculation verification for CyberKnife treatment as the secondary check.
Funding Support, Disclosures, and Conflict of Interest: This research is partially supported by Japan Agency for Medical Research and Development (AMED)
Contact Email: